Finance

Lists
500660:BOM
GlaxoSmithKline Pharmaceuticals Ltd
2 567,25 ₹
+1,75%
(+44,25) 1D
16 қаз., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 500660...
Open
2 527,25 ₹
High
2 572,40 ₹
Low
2 527,25 ₹
Mkt. cap
434,57 млрд
Avg. vol.
5,03 мың
Volume
2,37 мың
Dividend
2,22%
Quarterly dividend
14,25 ₹
Ex-dividend date
2026 ж. 29 мам.
P/E ratio
40,72
52-wk high
3 121,10 ₹
52-wk low
2 088,00 ₹
EPS
63,05 ₹
Shares outstanding
169,41 млн
No. of employees
3 мың
Open
2 527,25 ₹
High
2 572,40 ₹
Low
2 527,25 ₹
Mkt. cap
434,57 млрд
Avg. vol.
5,03 мың
Volume
2,37 мың
Dividend
2,22%
Quarterly dividend
14,25 ₹
Ex-dividend date
2026 ж. 29 мам.
P/E ratio
40,72
52-wk high
3 121,10 ₹
52-wk low
2 088,00 ₹
EPS
63,05 ₹
Shares outstanding
169,41 млн
No. of employees
3 мың
News stories
From web sources and news partners
Profile
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
About GlaxoSmithKline Pharmaceuticals Ltd
CEO-
Employees3,1 мың
Founded1924 ж. 13 қар.
Headquarters-
SectorPharmaceutical industry
Websiteindia-pharma.gsk.com
Last report
2026 ж. 03 там.
Fiscal period
Q1 2027
14,00 ₹ / 13,90 ₹
+0,72%beat
Revenue / Est. (INR)
9,38 млрд / 9,11 млрд
+3,00%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
9,80 млрд
10,41 млрд
9,95 млрд
9,38 млрд
Cost of goods sold
3,56 млрд
3,64 млрд
3,69 млрд
3,28 млрд
Cost of revenue
3,56 млрд
3,64 млрд
3,69 млрд
3,28 млрд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,38 млрд
1,52 млрд
2,95 млрд
1,59 млрд
Operating expense
3,06 млрд
3,26 млрд
2,84 млрд
3,31 млрд
Total operating expenses
6,62 млрд
6,90 млрд
6,53 млрд
6,59 млрд
Operating income
3,18 млрд
3,51 млрд
3,43 млрд
2,80 млрд
Other non operating income
335,70 млн
321,20 млн
-1,09 млрд
437,60 млн
EBT including unusual items
3,54 млрд
4,00 млрд
3,73 млрд
3,22 млрд
EBT excluding unusual items
3,51 млрд
3,82 млрд
2,94 млрд
3,22 млрд
Income tax expense
965,10 млн
1,04 млрд
952,41 млн
852,70 млн
Effective tax rate
27,26%
26,08%
25,53%
26,44%
Other operating expenses
1,51 млрд
1,54 млрд
-236,82 млн
1,56 млрд
Net income
2,57 млрд
2,96 млрд
2,78 млрд
2,37 млрд
Net profit margin
26,28%
28,39%
27,92%
25,27%
Earnings per share
-
-
-
14,00
Interest and investment income
-
-
657,30 млн
-
Interest expense
-5,10 млн
-11,90 млн
-6,12 млн
-9,70 млн
Net interest expenses
-5,10 млн
-11,90 млн
651,18 млн
-9,70 млн
Depreciation and amortization charges
174,30 млн
203,20 млн
131,74 млн
158,40 млн
EBITDA
3,35 млрд
3,61 млрд
3,52 млрд
2,89 млрд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары